<?xml version="1.0" encoding="UTF-8" standalone="yes"?><drugRecordsOutput><serviceExecutionTime>288</serviceExecutionTime><Drug id="78164"><DrugName>tegafur + uracil, TTY Biopharm</DrugName><DrugSynonyms><Name><Value>tegafur + uracil</Value></Name><Name><Value>UFUR, TTY Biopharm</Value></Name><Name><Value>tegafur + uracil, TTY Biopharm</Value></Name><Name><Value>74578-38-4</Value><Types><Type>CAS RN</Type></Types></Name><Name><Value>17902-23-7</Value><Types><Type>CAS RN</Type></Types></Name><Name><Value>66-22-8</Value><Types><Type>CAS RN</Type></Types></Name></DrugSynonyms><CompanyOriginator id="29954">TTY Biopharm Co Ltd</CompanyOriginator><CompaniesPrimary><Company id="29954">TTY Biopharm Co Ltd</Company></CompaniesPrimary><CrossReferences><SourceEntity id="29954" type="Company"><TargetEntity id="4295891167" type="organizationId">TTY Biopharm Co Ltd</TargetEntity></SourceEntity><SourceEntity id="651" type="ciIndication"><TargetEntity id="576" type="siCondition"/></SourceEntity><SourceEntity id="1545" type="Action"><TargetEntity id="4426" type="Mechanism">Immune Checkpoint Inhibitors</TargetEntity><TargetEntity id="1937" type="Mechanism">Anti-Tumor Associated Glycoprotein 72 (TAG-72)</TargetEntity><TargetEntity id="4644" type="Mechanism">Anti-PD-L1/ VISTA Immune Checkpoint</TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="L">Launched</PhaseHighest><PhaseHighestDetailed><FirstLaunched>Cancer - India - Dec-2009</FirstLaunched><FirstLaunched>Cancer - Malaysia - Dec-2009</FirstLaunched></PhaseHighestDetailed><IndicationsPrimary><Indication id="651">Cancer</Indication></IndicationsPrimary><ActionsSecondary><Action id="1545">Anticancer</Action><Action id="59620">Unspecified drug target</Action></ActionsSecondary><Technologies><Technology id="175">Drug combination</Technology><Technology id="585">Oral formulation</Technology><Technology id="586">Capsule formulation</Technology><Technology id="762">Small molecule therapeutic</Technology></Technologies><LastModificationDate>2014-10-10T17:12:13.000Z</LastModificationDate><ChangeDateLast>2016-08-31T00:00:00.000Z</ChangeDateLast><AddedDate>2012-05-23T00:00:00.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkType="Company" linkID="29954"&gt;TTY Biopharm&lt;/ulink&gt; has developed and launched  a capsule formulation of &lt;ulink linkType="Drug" linkID="12210"&gt;UFUR&lt;/ulink&gt;, a combination of tegafur and uracil, for the   oral treatment of non-small cell carcinoma. By December 2009,  the drug had been launched in India and Malaysia [&lt;ulink linkType="Reference" linkID="1292592"&gt;1292592&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="29954">TTY Biopharm Co Ltd</Company><Country id="IN">India</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate>2009-12-31T00:00:00.000Z</StatusDate><Source id="1292592" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="29954">TTY Biopharm Co Ltd</Company><Country id="MY">Malaysia</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate>2009-12-31T00:00:00.000Z</StatusDate><Source id="1292592" type="CORPORATE"/></DevelopmentStatusCurrent></IDdbDevelopmentStatus><ReasonsForUpdate><ReasonForUpdate><Reason>Editorial Amendments</Reason><Description>Minor editorial amendment</Description></ReasonForUpdate></ReasonsForUpdate><StructureSmiles><Smiles>c1c(c(=O)[nH]c(=O)n1C2CCCO2)F</Smiles><Smiles>c1c[nH]c(=O)[nH]c1=O.c1c(c(=O)[nH]c(=O)n1C2CCCO2)F</Smiles><Smiles>c1c[nH]c(=O)[nH]c1=O</Smiles></StructureSmiles><hasSWOTs>N</hasSWOTs></Drug></drugRecordsOutput>